|  |  |
| --- | --- |
| Vaccinated individuals enrolled (N) | 804 |
| Age (years); Mean (± SD) | 38.44 (± 11.47) |
| Gender (Male/Female) | 573/231 |
| Body mass index (kg/m2); Mean (± SD) | 24.68 (± 3.68) |
|  |
| History of laboratory confirmed COVID-19 at any time before vaccination; N (%)  | 56 (7) |
| Blood Group  | N (%) |
| B+ | 252 (31.3) |
| O+ | 225 (28) |
| A+ | 132 (16.4) |
| AB+ | 66 (8.2) |
| B- | 13 (1.6) |
| O- | 7 (0.9) |
| AB- | 4 (0.5) |
| A- | 4 (0.5) |
| No details | 101 (12.5) |
| Individuals with diabetes mellitus; N (%)On antidiabetic drugs; N (%) | 66 (8.2)51 (6.3) |
|
| Individuals with hypertension; N (%)On anti-hypertensive drugs; N (%) | 73 (9)71 (8.8) |
| Individuals with hypothyroidism; N (%)On thyroxine; N (%) | 28 (3.5)27 (3.3) |
| Individuals with asthma or COPD; N (%)On inhaled beta agonists; N (%)On inhaled steroids; N (%) | 10 (1.2)5 (0.6)4 (0.5) |
| Individuals with coronary artery disease; N (%)On antiplatelet drugs; N (%)On statins; N (%) | 5 (0.6)4 (0.5)3 (0.4) |
| Individuals with self-described allergy to any agent (environmental; household; medications etc); N (%) | 51 (6.3) |
| Individuals with past history of or active tuberculosis; N (%)On anti-tubercular therapy; N (%) | 4 (0.5)3 (0.4) |
| Individuals with epilepsy; N (%)On antiepileptic drugs; N (%) | 2 (0.25)2 (0.25) |
| Individuals with skin diseases; N (%) | 3 (0.4) |
| Individuals with rheumatoid arthritis; N (%) | 3 (0.4) |
| Individuals currently receiving other drugs | N (%) |
| Non-steroidal anti-inflammatory drugsAntibioticsAnticoagulants | 3 (0.4)1 (0.1)1 (0.1) |

**Table 1: Baseline characteristics of study participants**

***Abbreviations:*** SD, standard deviation; COPD, chronic obstructive pulmonary disease. All percentages in brackets are out of total enrolled vaccinees (N=804).